Orexo advances from Small to Mid Cap

Uppsala, Sweden – December 19, 2013 – Orexo AB, “Orexo” (OTCQX: ORXOY; NASDAQ
OMX Stockholm: ORX) was informed by NASDAQ OMX that Orexo will move to the Mid
Cap segment as of January 2, 2014.

The transfer is based on the Exchange’s six months review of the listed
companies’ market capitalization (market cap). At the second half-year review,
the market cap is based on a weighted average share price during November. The
Mid Cap segment includes companies with a market cap between MEUR 150 and MEUR
1,000. On November 29, Orexo had a market cap of MSEK 5,590, corresponding to
about MEUR 590.

For further information, please visit NASDAQ OMX webpage:
www.nasdaqomx.com/newsroom/pressreleases#nordicMarket


For further information, please contact:
Henrik Juuel, EVP and Chief Financial Officer
Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com


About Orexo AB
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv®, for maintenance
treatment of opioid dependence, in the United States. Zubsolv is a novel
formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and revenue
generating products currently marketed under license in the EU and US. Orexo AB,
with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange,
under the symbol “ORX”, and its American Depositary Receipts (ADRs) trade on the
OTCQX marketplace in the U.S. under the symbol “ORXOY”. The largest shareholders
are Novo A/S and HealthCap.

For information about Orexo AB, please visit www.orexo.com.


Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:45 am CET on December 19, 2013.